Information  X 
Enter a valid email address

Summit Corporation (SUMM)

  Print      Mail a friend

Tuesday 19 July, 2011

Summit Corporation

SUMMIT PRESENT POSITIVE RESULTS AT ICAD 2011

RNS Number : 6129K
Summit Corporation PLC
18 July 2011
 



Summit Corporation plc

("Summit" or "the Company")

 

 

SUMMIT PRESENTING POSITIVE ALZHEIMER'S DISEASE PROGRAMME RESULTS AT ICAD 2011

 

Oxford, UK, 19 July 2011, Summit Corporation plc (AIM: SUMM), a UK drug discovery company, is pleased to announce that it is presenting the recently reported positive results from its programme targeting Alzheimer's disease, and other neurological disorders, at the Alzheimer's Association International Conference on Alzheimer's Disease 2011 ('ICAD 2011') which is currently being held in Paris. 

 

Alzheimer's disease is a progressive and debilitating neurodegenerative disorder and is the most common form of dementia.  It remains an area of high unmet medical need with current treatment options only providing symptomatic relief. 

 

The title of the presentation is 'Reduction of Tau phosphorylation mediated by novel OGA inhibitors' and it highlights:

·    Summit's focus on a new and potentially disease modifying strategy for the treatment of Alzheimer's disease that targets the enzyme OGA (O-linked N-acetylglucosaminidase)

·    The identification and subsequent optimisation to generate extremely potent, selective and non-cytotoxic inhibitors of OGA using Summit's innovative Seglin™ technology drug discovery platform

·    Demonstration in a human cellular model that the Seglin OGA inhibitors reduce levels of an abnormal form of the protein Tau, found in the brain of Alzheimer's patients and which causes the formation of toxic 'tangles' and ultimately results in disease symptoms.

 

Interest in Tau protein as an approach for developing drugs to treat Alzheimer's disease continues to increase as evidenced by the growing number of peer-reviewed scientific publications.†  Tau protein plays a role in maintaining the healthy function of nerve cells in the brain but the formation of abnormal hyperphosphorylated Tau protein destabilises cells and results in formation of Tau protein aggregates ('tangles').  As results from Summit's early-stage programme show, inhibition of OGA by Seglins can reduce the levels of hyperphosphorylated Tau and potentially offers a new strategy for treating this disease.

 

A copy of the poster is available on request from investors@summitplc.com.

 

Dr Richard Storer, Chief Scientific Officer of Summit commented, "We are pleased to share these positive results at the 2011 ICAD meeting.  The identification of highly potent yet selective Seglins that inhibit OGA is a very important step forward as this enzyme target represents a new potential disease modifying approach for the treatment of Alzheimer's disease."

 

†          1. Targeting Tau Protein in Alzheimer's Disease, Cheng-Xin Gong, Inge Grundke-Iqbal and Khalid Iqbal, Drugs Aging 2010; 27 (5): 351-365.

            2. Advances in Tau-focused Drug Discovery for Alzheimer's Disease and Related Tauopathies, Kurt R. Brunden, John Q. Trojanowski, and Virginia M.-Y. Lee, Nature Reviews Drug Discovery, 2009 October; 8(10): 783-793.

 

- END -

 



For more information, please contact:

 

Summit

www.summitplc.com

Barry Price, PhD


Richard Pye, PhD

Tel: +44 (0)1235 443939



Singer Capital Markets (Nominated Adviser)


Shaun Dobson / Claes Spång

Tel: +44 (0)20 3205 7500



Peckwater PR


Tarquin  Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

 

 

Notes to Editors

 

About Summit

Summit is an Oxford, UK based drug discovery company with an innovative technology platform called Seglins for the discovery of new medicines, a portfolio of drug programme assets and a commercial strategy of signing multiple early-stage deals.

 

Seglin technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches.  Summit's internal research is currently focussed in the high-value therapy areas and the Company will further exploit the technology's wider potential through strategic alliances.  Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.

 

Summit's commercial strategy focuses on signing multiple early-stage drug programme and technology platform deals that generate upfront cash, remove development costs from the Company, and retain valuable upside potential.

 

Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.  Further information is available at www.summitplc.com.

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRADKFDPOBKDFOD